Phase 3 KEYNOTE-775/Study 309 trial of pembrolizumab plus lenvatinib meets dual primary endpoints of overall and progression-free survival in patients with advanced endometrial cancer following prior systemic therapy

This is confirmatory trial for KEYNOTE-146/Study 111, which supported FDA 2019 accelerated approval of this regimen for treating patients with advanced endometrial carcinoma, with disease progression following prior systemic therapy, not candidates for curative surgery/radiation.

Source:

Biospace Inc.